BCL6 and B-cell non-Hodgkin lymphoma: Alterations in BCL6 are mainly associated with B-cell lymphomas, however, in vitro upregulation of BCL6 has been identified as a possible regulator of response to therapy in EC through inhibition of transcription [30].